Project 2: Molecular and clinical inputs affecting optimization of glioma therapy Project Summary / Abstract: Glioblastomas (GBM) are the most malignant and common of the primary brain tumors and are divided into several molecular subgroups denoted PN-GBM, MES-GBM and CL-GBM. Because of a subset of cells with stem-like properties, these tumors are relatively insensitive to DNA damaging agents, such as radiation (XRT), and are consequently highly resistant to therapy. In PN-GBM the stem-like cells live adjacent to blood vessels, in the perivascular niche (PVN). In other GBM subtypes, stem-like cells are distributed throughout the tumors. In order to identify better GBM therapies, we need to improve our understanding of the biology of stem- and non-stem-like GBM cells as a function of molecular subtype. We have previously demonstrated that the dynamic inter-conversion of these two cell types occurs within hours of therapy and can be successfully mathematically modeled, providing a basis for optimizing radiation schedules to maximize survival in mouse models of PN-GBM. However, optimum radiation administration schedules for other GBM subtypes are unknown. Additionally, standard of care calls for the administration of adjuvant temozolomide (TMZ) concurrently with radiation. Based on our preliminary data, we hypothesize that (1) a mathematical model of radiation and TMZ response in MES-GBM will be different than that for PN-GBM, (2) a mathematical model of radiation and TMZ response in MES-GBM will be different than that for PN-GBM, (3) there are biological characteristics of GBM that, if altered, would fundamentally enhance the responses of all GBMs regardless of subtype. We propose three specific aims to test these hypotheses:
Aim 1 : Improve our understanding of the PVN in PN-GBM and use this understanding to optimize combined TMZ/XRT therapy.
Aim 2 : Create a mathematical model of radiation response in MES-GBM where the stem cells are more evenly distributed.
Aim 3. Identify strategies that would improve the standard of care for all GBM regardless of subtype. Our goal is to translate our findings into future clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
3U54CA193461-05S1
Application #
10134500
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Zahir, Nastaran Z
Project Start
Project End
Budget Start
2019-05-01
Budget End
2020-04-30
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Ozawa, Tatsuya; Arora, Sonali; Szulzewsky, Frank et al. (2018) A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-?B. Cell Rep 23:3787-3797
Cimino, Patrick J; Kim, Youngmi; Wu, Hua-Jun et al. (2018) Increased HOXA5 expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastoma. Genes Dev 32:512-523
Stein, Shayna; Zhao, Rui; Haeno, Hiroshi et al. (2018) Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients. PLoS Comput Biol 14:e1005924
Hinohara, Kunihiko; Wu, Hua-Jun; Vigneau, Sébastien et al. (2018) KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. Cancer Cell 34:939-953.e9
Smith, Zachary D; Shi, Jiantao; Gu, Hongcang et al. (2017) Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer. Nature 549:543-547
Campbell, Peter T; Rebbeck, Timothy R; Nishihara, Reiko et al. (2017) Proceedings of the third international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control 28:167-176
Temko, Daniel; Cheng, Yu-Kang; Polyak, Kornelia et al. (2017) Mathematical Modeling Links Pregnancy-Associated Changes and Breast Cancer Risk. Cancer Res 77:2800-2809
Malone, Clare F; Emerson, Chloe; Ingraham, Rachel et al. (2017) mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors. Cancer Discov 7:1450-1463
Chakrabarti, Shaon; Michor, Franziska (2017) Pharmacokinetics and Drug Interactions Determine Optimum Combination Strategies in Computational Models of Cancer Evolution. Cancer Res 77:3908-3921
Yu, Vionnie W C; Yusuf, Rushdia Z; Oki, Toshihiko et al. (2017) Epigenetic Memory Underlies Cell-Autonomous Heterogeneous Behavior of Hematopoietic Stem Cells. Cell 168:944-945

Showing the most recent 10 out of 36 publications